+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

KOL Perspectives: Rituximab Use in Lupus

  • PDF Icon

    Drug Pipelines

  • 37 Pages
  • July 2018
  • Region: Global
  • GlobalData
  • ID: 4701802
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.

Questions topics -
  • Current & future use of RTX in lupus

  • Views on RTX’s Phase II/III EXPLORER trial re-analysis

  • Opinion on data demonstrating that RTX is effective for the management of refractory SLE

  • Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy

  • Lupus patients most suitable for RTX + BEL combination therapy

  • Use of RTX + BEL combination therapy

Key Highlights
  • Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price

  • Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results

  • Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.

  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based

  • Interviews performed during Q2 2018

KOL data is analyzed to produce -
  • Charts summarizing KOL opinions

  • Chart call-outs of key information & details

  • KOL quotes

  • Summary of KOL reporting trends

  • Insight from Sociable Pharma's analysts

Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus

  • Includes insight & recommendations from our disease-specific healthcare analysts

  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary

  • Background

  • Research Panel Composition

  • Results & Implications

  • Appendix



Companies Mentioned

A selection of companies mentioned in this report includes:

  • Roche

  • GSK